MacroGenics Provides Vobramitamab Duocarmazine Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St futures mixed ahead of CPI, bank earnings; US-Iran tensions in focus
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
BTIG Downgrades MacroGenics (MGNX) to Neutral
July 31, 2024 4:18 PM EDTBTIG analyst Kaveri Pohlman downgraded MacroGenics (NASDAQ: MGNX) from Buy to Neutral.
The analyst comments "MacroGenics has discontinued the Tamarack study, evaluating vobra duo for mCRPC, after a review of its risk/benefit profile. This decision follows the study's IDMC recommendation to discontinue treatment for the remaining study participants who were eligible to receive additional doses. For reference, the majority... More
